Psychopharmacologic treatment of children prenatally exposed to drugs of abuse

Leslie Hulvershorn, Kristen M. Schroeder, Logan K. Wink, Craig A. Erickson, Christopher J. McDougle

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective This pilot study compared the pharmacologic treatment history and clinical outcomes observed in pediatric outpatients with psychiatric disorders exposed to drugs of abuse in utero to those of an age-matched, sex-matched and psychiatric disorder-matched, non-drug-exposed group. Methods In this matched cohort study, medical records of children treated at an academic, child and adolescent psychiatry outpatient clinic were reviewed. Children with caregiver-reported history of prenatal drug exposure were compared with a non-drug-exposed control group being cared for by the same providers. Patients were rated with the Clinical Global Impressions - Severity scale (CGI-S) throughout treatment. The changes in pre-treatment and post-treatment CGI-S scores and the total number of medication trials were determined between groups. Results The drug-exposed group (n=30) had a higher total number of lifetime medication trials compared with the non-drug-exposed group (n=28) and were taking significantly more total medications, at their final assessment. Unlike the non-drug-exposed group, the drug-exposed group demonstrated a lack of clinical improvement. Conclusions These results suggest that in utero drug-exposed children may be more treatment-refractory to or experience greater side effects from the pharmacologic treatment of psychiatric disorders than controls, although we cannot determine if early environment or drugs exposure drives these findings.

Original languageEnglish
Pages (from-to)164-172
Number of pages9
JournalHuman Psychopharmacology
Volume30
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Street Drugs
Psychiatry
Pharmaceutical Preparations
Therapeutics
Adolescent Psychiatry
Child Psychiatry
Ambulatory Care Facilities
Caregivers
Medical Records
Cohort Studies
Outpatients
History
Pediatrics
Control Groups

Keywords

  • children
  • prenatal drug exposure
  • psychopharmacology

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)

Cite this

Psychopharmacologic treatment of children prenatally exposed to drugs of abuse. / Hulvershorn, Leslie; Schroeder, Kristen M.; Wink, Logan K.; Erickson, Craig A.; McDougle, Christopher J.

In: Human Psychopharmacology, Vol. 30, No. 3, 01.05.2015, p. 164-172.

Research output: Contribution to journalArticle

Hulvershorn, Leslie ; Schroeder, Kristen M. ; Wink, Logan K. ; Erickson, Craig A. ; McDougle, Christopher J. / Psychopharmacologic treatment of children prenatally exposed to drugs of abuse. In: Human Psychopharmacology. 2015 ; Vol. 30, No. 3. pp. 164-172.
@article{2458660963fd46cd8e36ab1d5df6833c,
title = "Psychopharmacologic treatment of children prenatally exposed to drugs of abuse",
abstract = "Objective This pilot study compared the pharmacologic treatment history and clinical outcomes observed in pediatric outpatients with psychiatric disorders exposed to drugs of abuse in utero to those of an age-matched, sex-matched and psychiatric disorder-matched, non-drug-exposed group. Methods In this matched cohort study, medical records of children treated at an academic, child and adolescent psychiatry outpatient clinic were reviewed. Children with caregiver-reported history of prenatal drug exposure were compared with a non-drug-exposed control group being cared for by the same providers. Patients were rated with the Clinical Global Impressions - Severity scale (CGI-S) throughout treatment. The changes in pre-treatment and post-treatment CGI-S scores and the total number of medication trials were determined between groups. Results The drug-exposed group (n=30) had a higher total number of lifetime medication trials compared with the non-drug-exposed group (n=28) and were taking significantly more total medications, at their final assessment. Unlike the non-drug-exposed group, the drug-exposed group demonstrated a lack of clinical improvement. Conclusions These results suggest that in utero drug-exposed children may be more treatment-refractory to or experience greater side effects from the pharmacologic treatment of psychiatric disorders than controls, although we cannot determine if early environment or drugs exposure drives these findings.",
keywords = "children, prenatal drug exposure, psychopharmacology",
author = "Leslie Hulvershorn and Schroeder, {Kristen M.} and Wink, {Logan K.} and Erickson, {Craig A.} and McDougle, {Christopher J.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/hup.2467",
language = "English",
volume = "30",
pages = "164--172",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Psychopharmacologic treatment of children prenatally exposed to drugs of abuse

AU - Hulvershorn, Leslie

AU - Schroeder, Kristen M.

AU - Wink, Logan K.

AU - Erickson, Craig A.

AU - McDougle, Christopher J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Objective This pilot study compared the pharmacologic treatment history and clinical outcomes observed in pediatric outpatients with psychiatric disorders exposed to drugs of abuse in utero to those of an age-matched, sex-matched and psychiatric disorder-matched, non-drug-exposed group. Methods In this matched cohort study, medical records of children treated at an academic, child and adolescent psychiatry outpatient clinic were reviewed. Children with caregiver-reported history of prenatal drug exposure were compared with a non-drug-exposed control group being cared for by the same providers. Patients were rated with the Clinical Global Impressions - Severity scale (CGI-S) throughout treatment. The changes in pre-treatment and post-treatment CGI-S scores and the total number of medication trials were determined between groups. Results The drug-exposed group (n=30) had a higher total number of lifetime medication trials compared with the non-drug-exposed group (n=28) and were taking significantly more total medications, at their final assessment. Unlike the non-drug-exposed group, the drug-exposed group demonstrated a lack of clinical improvement. Conclusions These results suggest that in utero drug-exposed children may be more treatment-refractory to or experience greater side effects from the pharmacologic treatment of psychiatric disorders than controls, although we cannot determine if early environment or drugs exposure drives these findings.

AB - Objective This pilot study compared the pharmacologic treatment history and clinical outcomes observed in pediatric outpatients with psychiatric disorders exposed to drugs of abuse in utero to those of an age-matched, sex-matched and psychiatric disorder-matched, non-drug-exposed group. Methods In this matched cohort study, medical records of children treated at an academic, child and adolescent psychiatry outpatient clinic were reviewed. Children with caregiver-reported history of prenatal drug exposure were compared with a non-drug-exposed control group being cared for by the same providers. Patients were rated with the Clinical Global Impressions - Severity scale (CGI-S) throughout treatment. The changes in pre-treatment and post-treatment CGI-S scores and the total number of medication trials were determined between groups. Results The drug-exposed group (n=30) had a higher total number of lifetime medication trials compared with the non-drug-exposed group (n=28) and were taking significantly more total medications, at their final assessment. Unlike the non-drug-exposed group, the drug-exposed group demonstrated a lack of clinical improvement. Conclusions These results suggest that in utero drug-exposed children may be more treatment-refractory to or experience greater side effects from the pharmacologic treatment of psychiatric disorders than controls, although we cannot determine if early environment or drugs exposure drives these findings.

KW - children

KW - prenatal drug exposure

KW - psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=84928118985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928118985&partnerID=8YFLogxK

U2 - 10.1002/hup.2467

DO - 10.1002/hup.2467

M3 - Article

C2 - 25737371

AN - SCOPUS:84928118985

VL - 30

SP - 164

EP - 172

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 3

ER -